Below is STUDY UPDATED ON JUNE 12TH suggest the Interim DMC results would be out anytime soon.
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
First received: September 17, 2002
Last updated: June 12, 2014
Last verified: June 2014
This clinical trial is approved by the FDA for all types of solid tumor ... II portion, testing for efficacy, without the need for another FDA review and on May 30, 2014 - The Food and Drug Administration (FDA) has developed four distinct and .... A Priority Review designation will direct overall attention ...
Fast Track, Breakthrough Therapy, Accelerated Approval and Priority Review
Expediting Availability of New Drugs for Patients with Serious Conditions
Speeding the development and availability of drugs that treat serious diseases are in everyone's interest, especially when the drugs are the first available treatment or have advantages over existing treatments. The Food and Drug Administration (FDA) has developed four distinct and successful approaches to making such drugs available as rapidly as possible: Priority Review, Accelerated Approval, Fast Track Designation, and breakthrough therapy designation. Because each of these approaches implies speed, there can be confusion about the specific meaning of each and the distinctions among them.
The following summary describes each element, how they differ, and how they complement each other.
Northwest Biotherapeutics (NWBO) Rings the Opening Bell as NASDAQ on Face Book December 18, 2012 In celebration of the Company's recent financing and up-listing to the NASDAQ Captial Market, Northwest Bio rang the Opening Bell at the NASDAQ Capital market
The Company has an approval for selling DCVax-L in the UK that is similar to that in Germany except that there is no potential for reimbursement from the UK national health insurance program. We may hear more about the UK once Germany begins to get up and running. Patients with adequate resources can pay for and gain access to DCVax-L in the UK.
DCVax-L DMC Phase III due 2-7-14 per the biopharmcatalyst site.
Selection for inclusion in these indexes is based upon market capitalization and other market factors relating to a company and its stock.
Soon will have $20 range...
We are heading for better results on DCVax Direct and its better than ICPT which open $440 after close at $70 in March 2014
Don't worry AF has to keep his shiiity mouth shut for ever on NWBO after that Shity article he sends out on NWBO largest booth and DCVax Direct results.
By 27th June NWBO shall be at least $1Billion Mkt Cap and for which the stock price has to be $20 or above.